Uso de bisfosfonatos adjuvantes e outros agentes modificadores ósseos no câncer de mama: atualização da diretriz ASCO-OH (CCO).

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update – Journal of Clinical Oncology

Comentário no Twitter

Out on @JCO_ASCO the new ASCO/OH guidelines for adjuvant bisphosphonates in BC

Important to weight risks and benefits based on the risk profile of the disease, financial toxicity, drug availability, patient preferences, comorbidities & life expectancy. https://t.co/6noyYplALB

— Paolo Tarantino (@PTarantinoMD) January 18, 2022